Total Funding
66
10
Total FundingSeries A raised
Growth Score
-16 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
53831
Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.
- Ryutaro Shimazaki: Chief Development Officer
- Takeshi Takahashi: Chief Financial Officer & Co-Founder
About the Company
Renalys Pharma is a clinical-stage biopharmaceutical company based in Japan that focuses on developing treatments for unmet needs in the management of kidney disease for Japanese and Asian patients.2 The company's lead asset is sparsentan, an oral Dual Endothelin Angiotensin Receptor Antagonist (3$\text{DEARA}$), which is licensed for
development and commercialization in Asian territories.4
